pms-pantoprazole tablet (delayed-release)
pharmascience inc - pantoprazole (pantoprazole sodium) - tablet (delayed-release) - 20mg - pantoprazole (pantoprazole sodium) 20mg - proton-pump inhibitors
pms-pantoprazole tablet (delayed-release)
pharmascience inc - pantoprazole (pantoprazole sodium) - tablet (delayed-release) - 40mg - pantoprazole (pantoprazole sodium) 40mg - proton-pump inhibitors
ag-pantoprazole sodium tablet (delayed-release)
angita pharma inc. - pantoprazole (pantoprazole sodium sesquihydrate) - tablet (delayed-release) - 20mg - pantoprazole (pantoprazole sodium sesquihydrate) 20mg - proton-pump inhibitors
ag-pantoprazole sodium tablet (delayed-release)
angita pharma inc. - pantoprazole (pantoprazole sodium sesquihydrate) - tablet (delayed-release) - 40mg - pantoprazole (pantoprazole sodium sesquihydrate) 40mg - proton-pump inhibitors
apo-pantoprazole 40mg tablets enteric-coated
apotex inc. - pantoprazole (pantoprazole sodium sesquihydrate) - tablets enteric-coated - 40mg
apo-pantoprazole 20mg tablets enteric-coated
apotex inc. - pantoprazole (pantoprazole sodium sesquihydrate) - tablets enteric-coated - 20mg
pantoprazole an pantoprazole (as sodium sesquihydrate) 40 mg enteric-coated tablet blister pack.
amneal pharma australia pty ltd - pantoprazole sodium sesquihydrate -
pantoprazole an pantoprazole (as sodium sesquihydrate) 20 mg enteric-coated tablet blister pack.
amneal pharma australia pty ltd - pantoprazole sodium sesquihydrate -
pantoprazole amneal pantoprazole (as sodium sesquihydrate) 40 mg enteric-coated tablet blister pack
amneal pharma australia pty ltd - pantoprazole -
pantoprazole sodium- pantoprazole sodium tablet, delayed release
nucare pharmaceuticals, inc. - pantoprazole sodium (unii: 6871619q5x) (pantoprazole - unii:d8tst4o562) - pantoprazole sodium delayed-release tablets usp are indicated for: pantoprazole sodium delayed-release tablets usp are indicated in adults for the short-term treatment (up to 8 weeks) in the healing and symptomatic relief of erosive esophagitis. for those adult patients who have not healed after 8 weeks of treatment, an additional 8 week course of pantoprazole sodium delayed-release tablets usp may be considered. safety of treatment beyond 8 weeks in pediatric patients has not been established. pantoprazole sodium delayed-release tablets usp are indicated for maintenance of healing of erosive esophagitis and reduction in relapse rates of daytime and nighttime heartburn symptoms in adult patients with gerd. controlled studies did not extend beyond 12 months. pantoprazole sodium delayed-release tablets usp are indicated for the long-term treatment of pathological hypersecretory conditions, including zollinger-ellison syndrome. pantoprazole sodium delayed-release tablets are contraindicated in patients with know